Serpin B-10 (Recombinant)
- Expression system
- HEK293
- Cat. #
- REC-SerpinB10
In stock
- SKU
- REC-SerpinB10
Target Overview
Serpin B-10 (gene: SERPINB10; UniProt P48595), also known as Bomapin and Peptidase Inhibitor 10 (PI-10), is a 397-amino-acid member of the clade B (ov-serpin) branch of the serpin superfamily. Unlike secreted serpins, clade B members lack a signal peptide and function intracellularly; Serpin B-10 localises primarily to the nucleus and cytoplasm, positioning it to regulate protease activities in compartments distinct from the classical extracellular serpin targets. This recombinant is produced in HEK293 mammalian cells, providing a eukaryotic expression environment that supports native-like folding and post-translational modifications relevant to the full-length 397-residue human sequence. Mammalian expression is particularly appropriate for a nuclear serpin whose inhibitory conformation depends on accurate tertiary folding of the reactive centre loop. Researchers use this recombinant in several in-vitro contexts. As a protease inhibitor standard, it can be applied in activity assays designed to characterise substrate and inhibitor selectivity. Because recombinant Serpin B-10 carries the full antigenic sequence, it serves as a reliable positive control and loading standard for Western blot and immunohistochemistry experiments — researchers validating the matched Triple Point Biologics antibody (RP-SerpinB10) can pair the two reagents directly for band-identity confirmation and titration. The recombinant is also well suited as a calibration standard in quantitative ELISA development, and as a binding partner in protein–protein interaction studies examining serpin–protease complex formation. Its nuclear localisation and reported involvement in TNF-induced apoptosis make it a useful tool antigen in cell-biology research aimed at dissecting intracellular protease regulation.
Background
Applications
- Protease inhibition activity assay — assess inhibitory kinetics against candidate serine protease targets in a defined biochemical system
- Inhibitor selectivity and IC50 determination — use as a serpin competitor in small-molecule or peptide inhibitor screens
- Western blot positive control — confirm band identity and apparent molecular weight in cell or tissue lysate experiments
- IHC/IF antibody titration standard — recombinant protein spotted on nitrocellulose or tissue microarray for optimising RP-SerpinB10 antibody concentration
- Antibody validation paired standard — co-run with matched Triple Point Biologics antibody (RP-SerpinB10) to confirm epitope recognition and lot-to-lot consistency
- Quantitative ELISA calibration curve — serve as a reference antigen for sandwich or competitive ELISA development in expression profiling studies
- Protein–protein interaction binding assay — immobilised or solution-phase binding experiments to map serpin–protease or serpin–cofactor complexes
- Macrophage or neutrophil stimulation studies — exogenous addition to in-vitro immune cell assays to probe SERPINB10-dependent polarisation or activation phenotypes
References
- Kong W et al. SERPINB10 promotes neutrophilic airway inflammation in asthma. Am J Respir Cell Mol Biol. 2026. doi:10.1165/rcmb.2024-0580OC. PMID: 41072019.
- Zhao L et al. SERPINB10 promotes macrophage M2 polarization and airway inflammation in asthma. Respir Res. 2025. doi:10.1186/s12931-025-03252-3. PMID: 40349036.
- Nie Q et al. Neuro-immune-related gene signatures define molecular subtypes and prognostic score in bladder cancer with SERPINE2 as a potential therapeutic target. PeerJ. 2026. doi:10.7717/peerj.20917. PMID: 41800135.
- Deng Z et al. Increased Expression of SERPINB10 Associated with Postoperative Recurrence in Chronic Rhinosinusitis with Nasal Polyps. Dis Markers. 2022. doi:10.1155/2022/7164318. PMID: 36398030.
- Cai ML et al. Proteomic Analyses Reveal Higher Levels of Neutrophil Activation in Men Than in Women With Systemic Lupus Erythematosus. Front Immunol. 2022. doi:10.3389/fimmu.2022.911997. PMID: 35799787.
Additional Specifications
| Storage Buffer | 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol |
|---|---|
| Endotoxin Level | <0.1 EU/µg by LAL |
| Purity (%) | >90% by SDS-PAGE |
| Expression System | HEK293 |
| Subcellular Localization | Secreted; blood plasma |
Frequently Asked Questions
What is the expected molecular weight of recombinant Serpin B-10 on SDS-PAGE and Western blot?
Serpin B-10 is a 397-amino-acid protein with a calculated molecular weight of approximately 44.6 kDa. On reducing SDS-PAGE, the recombinant produced in HEK293 cells typically migrates at 45–48 kDa; the slight upward shift relative to the theoretical mass is consistent with glycosylation and other post-translational modifications supported by the mammalian expression system. On Western blot, expect a single predominant band in that same 45–48 kDa range. Anomalous migration is not commonly reported for this serpin.
Is recombinant Serpin B-10 the full-length protein or a processed fragment? Does it undergo autocleavage?
This recombinant corresponds to the full-length 397-residue human Serpin B-10 sequence (UniProt P48595, isoform 1). As a clade B ov-serpin, Serpin B-10 does not possess a signal peptide and is not subject to the secretory processing seen in clade A serpins. Autocleavage at the reactive centre loop (RCL) can occur if the protein is incubated with a cognate protease that cleaves without forming a stable inhibitory complex; under normal storage conditions (no protease present), the intact inhibitory form is maintained. Verify integrity by SDS-PAGE before each experiment.
What protease does Serpin B-10 inhibit and what substrate or protease should I use to measure its inhibitory activity in vitro?
Serpin B-10 (Bomapin) has been reported to inhibit serine proteases, with tryptase and certain cathepsin G-related activities cited in the literature as candidate targets. For in vitro activity assays, a standard approach is to pre-incubate recombinant Serpin B-10 with the target serine protease (e.g., tryptase β1) for 15–30 min at 37 °C in assay buffer, then add a fluorogenic substrate such as Boc-Phe-Ser-Arg-AMC and measure fluorescence at Ex/Em 380/460 nm. Serpin B-10 acts as a stoichiometric inhibitor, so titrate the protease:inhibitor molar ratio (typically 1:1 to 1:5) rather than deriving a classical enzyme IC50.
What buffer conditions are recommended for Serpin B-10 protease inhibition assays and is the storage buffer compatible?
The product is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. This buffer is compatible with most serine protease activity assays, though glycerol carryover above ~2% can affect some fluorescent readouts. For sensitive fluorogenic assays, dilute the recombinant at least 1:5 into assay buffer (e.g., 50 mM HEPES pH 7.4, 150 mM NaCl, 0.01% Tween-20) before use. Avoid reducing agents such as DTT above 1 mM, as high concentrations can destabilize the RCL conformation critical for inhibitory activity. Working pH range 6.8–8.0 is generally well-tolerated.
What starting concentration of recombinant Serpin B-10 should I use in a stoichiometric inhibition assay?
Because serpins act as suicide substrate inhibitors rather than catalytic inhibitors, dosing is expressed as a molar ratio relative to the target protease rather than as an IC50. A practical starting point is 200–500 nM recombinant Serpin B-10 paired with 50–100 nM protease, giving a 2–10 fold molar excess of inhibitor. Confirm complete inhibition by residual substrate cleavage and titrate downward to determine the stoichiometry of inhibition (SI) value for your specific protease preparation. Purity is >90–95% by SDS-PAGE, so mass-based concentration estimates closely reflect active protein, though functional titration against a known protease standard is still advised.
Can I use recombinant Serpin B-10 as a positive control on Western blot with the matched TPB antibody RP-SerpinB10?
Yes — this is one of the primary intended uses of REC-SerpinB10 alongside the matched rabbit polyclonal RP-SerpinB10 (/anti-serpin-b10-rabbit-polyclonal-antibody). The antibody and recombinant are produced and validated in the same laboratory, ensuring epitope compatibility. Load 20–50 ng of recombinant per lane on a 10–12% SDS-PAGE gel; this typically yields a clean, well-resolved band at 45–48 kDa that serves as an unambiguous size reference when probing cell or tissue lysates. RP-SerpinB10 is validated for Western blot; the recombinant positive control is particularly useful when working with sample types where endogenous Serpin B-10 expression is low or uncertain.
How much recombinant Serpin B-10 should I load for Western blot positive control and what band should I expect?
Load 20–50 ng per lane when using RP-SerpinB10 at standard working dilutions (typically 1:500–1:2,000 for Western blot; confirm with the antibody datasheet). At 50 ng with a sensitive HRP-chemiluminescence detection system, the band at 45–48 kDa is clearly visible without background interference. If your endogenous lysate lanes contain high total protein (20–40 µg), run the recombinant in a flanking lane rather than mixing, to avoid signal saturation. The HEK293 expression system means the recombinant band migration closely mirrors endogenous human Serpin B-10, minimising ambiguity in band assignment.
How should I handle, dilute, and store recombinant Serpin B-10 to maintain activity and avoid freeze-thaw degradation?
REC-SerpinB10 is shipped and stored at -20 °C in single-use aliquots in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. Thaw on ice, mix gently by pipetting — do not vortex — and use within the same working session. The 10% glycerol in the storage buffer provides cryoprotection; repeated freeze-thaw cycles progressively denature the RCL and reduce inhibitory activity. If a stock will be used across multiple days, prepare working aliquots of the diluted protein in assay buffer supplemented with 0.1% BSA and store at 4 °C for no more than 48 hours. Do not re-freeze thawed material.
Validation imagery coming soon
Western blot validation figures for REC-SerpinB10 will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.